Lymphoma

Consider surgery for primary prevention in people with obesity, researchers suggest

Response rate exceeds 60%, with 15- to 20-month duration with epcoritamab

One of 40 patients changed treatment but all remained on brentuximab regardless of scan results

Increased risk for non-melanoma skin cancer, MDS, AML versus the general population

Patients with higher diversity also had lower rates of acute graft-versus-host disease

Researchers call study "practice changing," although outside experts urge caution

More than 80% of responding patients remained in response at 4 years

News, features, and commentary about cancer-related issues

73% of patients with prior exposure to covalent BTK inhibitors responded

News, features, and commentary about cancer-related issues

News, features, and commentary about cancer-related issues

Here's how the medical team diagnosed and treated the rare inflammatory skin disorder

Approval of glofitamab was based on a phase I/II study that showed a 56% overall response rate

News, features, and commentary about cancer-related issues